Literature DB >> 8717414

Pharmacology of endothelins: vascular preparations for studying ETA and ETB receptors.

G Caló1, J P Gratton, S Télémaque, P D'Orléans-Juste, D Regoli.   

Abstract

Three rabbit vessels, the carotid and pulmonary arteries and the jugular vein were investigated to identify vascular monoreceptor systems (either ETA or ETB) to be used in structure-activity studies on endothelins and their antagonists. The RbCA has been found to behave as a monoreceptor ETA preparation, since it shows much greater sensitivity to ET-1 than to ET-3 and is insensitive to IRL 1620. The contractile response of the RbCA to ET-1 is reduced in the presence of BQ-123 but is not influenced by BQ-788. The RbPA behaves as a pure ETB system when stimulated with the ETB selective agonist IRL 1620. The contractile effect of IRL 1620 is reduced in the presence of BQ-788 but is not influenced by BQ-123. The RbJV responds to ET-1 and to IRL 1620 with contractions that are reduced by both BQ-123 and BQ-788, respectively. THe RbJV appears to be a mixed ETA and ETB system in which the two functional sites play an equivalent role in the stimulatory contractile response. Thus, contractile ETA and ETB receptors have been found in arterial and venous vessels of the rabbit and some of these vessels provide sensitive and selective (either ETA or ETB) preparations that appear to be adequate for pharmacological studies on ET receptor agonists or antagonists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717414     DOI: 10.1007/BF00248458

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  20 in total

1.  Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor.

Authors:  M Ihara; K Noguchi; T Saeki; T Fukuroda; S Tsuchida; S Kimura; T Fukami; K Ishikawa; M Nishikibe; M Yano
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  Pharmacology of endothelin-1 in vivo in humans.

Authors:  W G Haynes; J G Clarke; J R Cockcroft; D J Webb
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

3.  Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein.

Authors:  W A Bax; E Bos; P R Saxena
Journal:  Eur J Pharmacol       Date:  1993-08-03       Impact factor: 4.432

4.  Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist.

Authors:  M Clozel; V Breu; K Burri; J M Cassal; W Fischli; G A Gray; G Hirth; B M Löffler; M Müller; W Neidhart
Journal:  Nature       Date:  1993-10-21       Impact factor: 49.962

5.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

6.  Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores.

Authors:  S Karne; C K Jayawickreme; M R Lerner
Journal:  J Biol Chem       Date:  1993-09-05       Impact factor: 5.157

7.  Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors.

Authors:  T D Warner; G H Allcock; E J Mickley; R Corder; J R Vane
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

8.  Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery.

Authors:  T Fukuroda; S Ozaki; M Ihara; K Ishikawa; M Yano; M Nishikibe
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

Review 9.  Bradykinin receptor types and B2 subtypes.

Authors:  D Regoli; F Gobeil; Q T Nguyen; D Jukic; P R Seoane; J M Salvino; D G Sawutz
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

10.  Evidence for a differential location of vasoconstrictor endothelin receptors in the vasculature.

Authors:  S Moreland; D McMullen; B Abboa-Offei; A Seymour
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more
  5 in total

1.  Characterization of endothelin receptors in the human umbilical artery and vein.

Authors:  G Bogoni; A Rizzi; G Calo; C Campobasso; P D'Orleans-Juste; D Regoli
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

2.  Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.

Authors:  Nathan R Tykocki; Cheryl E Gariepy; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-03-18       Impact factor: 4.030

3.  Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.

Authors:  Stephanie W Watts; Gregory D Fink; Carrie A Northcott; James J Galligan
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

4.  Functional characterization and expression of endothelin receptors in rat carotid artery: involvement of nitric oxide, a vasodilator prostanoid and the opening of K+ channels in ETB-induced relaxation.

Authors:  Carlos R Tirapelli; Debora A Casolari; Alvaro Yogi; Augusto C Montezano; Rita C Tostes; Eurode Legros; Pedro D'Orléans-Juste; Ana M de Oliveira
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

Review 5.  Vascular dysfunction as a target for adjuvant therapy in cerebral malaria.

Authors:  Leonardo José de Moura Carvalho; Aline da Silva Moreira; Cláudio Tadeu Daniel-Ribeiro; Yuri Chaves Martins
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08       Impact factor: 2.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.